CROI 2026: Advances in Epidemiology and Treatment of Viral Hepatitis.

The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted hepatitis B outcomes in people with HIV on non-hepatitis B-active regimens. Advances in hepatitis B treatment were covered, with some abstracts highlighting novel investigational agents such as antivirals or immune modulators. Data were presented from a phase III trial examining the safety and efficacy of bulevirtide, an investigational agent for hepatitis D treatment. Pharmacokinetic data in animal models from a long-acting injectable intraparticle coformulation of glecaprevir/pibrentasvir were presented for the treatment of hepatitis C. Several abstracts highlighted interventions to increase hepatitis C virus infection detection rates, such as rapid or point-of-care testing, and others focused on improving linkage to care to increase hepatitis C treatment and sustained virologic response rates. Finally, a single abstract showed 2 investigational agents with antiviral activity for hepatitis E virus infection.